VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain. In this study, the investigators aimed to assess safety and response to a new PD-1 inhibitor-based triple-drug combination regimen (venetoclax + hypomethylation agent + PD-1 inhibitor) in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients, or who had positive minimal residual disease.

Trial Details

NCT ID
NCT06536959
Phase
PHASE2
Sponsor
Beijing 302 Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients diagnosed with relapsed and refractory acute myeloid leukemia (AML) and patients diagnosed with myelodysplastic syndrome (MDS) who require…
  • Patients who did not respond or had disease recurrence after 1 course of induction chemotherapy or had positive immune residues after induction che…
  • Voluntarily participate in clinical research and sign an informed consent form and be willing to follow and be able to complete all experimental pr…
  • The toxic and side effects caused by the last treatment should be recovered.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →